Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $7.43 USD
Change Today -0.05 / -0.67%
Volume 93.6K
RPRX On Other Exchanges
As of 8:10 PM 07/30/15 All times are local (Market data is delayed by at least 15 minutes).

repros therapeutics inc (RPRX) Snapshot

Previous Close
Day High
Day Low
52 Week High
09/2/14 - $22.55
52 Week Low
10/21/14 - $5.92
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

repros therapeutics inc (RPRX) Related Bloomberg News

View More Bloomberg News

repros therapeutics inc (RPRX) Related Businessweek News

No Related Businessweek News Found

repros therapeutics inc (RPRX) Details

Repros Therapeutics Inc., a biopharmaceutical company, focuses on the development of new drugs to treat hormonal and reproductive system disorders for male and female in the United States. Its product portfolio includes Androxal, an oral therapy, which is in Phase III clinical trials for the treatment of low testosterone due to secondary hypogonadism; and Proellex that is in Phase IIB clinical trials for the treatment of symptoms associated with uterine fibroids, as well as in Phase II clinical trial for the treatment of endometriosis. The company has a license agreement with the National Institutes of Health to develop and commercialize Proellex. Repros Therapeutics Inc. was founded in 1987 and is based in The Woodlands, Texas.

26 Employees
Last Reported Date: 05/7/15
Founded in 1987

repros therapeutics inc (RPRX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $891.0K
Chief Financial Officer, Chief Accounting Off...
Total Annual Compensation: $325.0K
Senior Vice President of Clinical & Regulator...
Total Annual Compensation: $250.0K
Chief Medical Officer
Total Annual Compensation: $200.0K
Vice President of Research & Development
Total Annual Compensation: $190.0K
Compensation as of Fiscal Year 2014.

repros therapeutics inc (RPRX) Key Developments

Repros Therapeutics Inc.(NasdaqCM:RPRX) dropped from Russell 2000 Index

Repros Therapeutics Inc. will be removed from Russell 2000 Index

Repros Therapeutics Inc.(NasdaqCM:RPRX) dropped from Russell 3000 Index

Repros Therapeutics Inc. will be removed from the Russell 3000 Index.

Repros Therapeutics Inc. Announces Date of FDA Advisory Committee Review of NDA for its Enclomiphene Product Candidate

Repros Therapeutics Inc. announced that the Division of Bone, Reproductive and Urologic Products of the U.S. Food and Drug Administration (FDA) has scheduled the advisory committee to review the Company's New Drug Application (NDA) for its enclomiphene product candidate, formerly known as AndroxalÂ, on November 3, 2015. The Company submitted the NDA on January 30, 2015. The FDA accepted the NDA for review on April 1, 2015 and later assigned a Prescription Drug User Fee Act (PDUFA) goal date of November 30, 2015.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
RPRX:US $7.43 USD -0.05

RPRX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for RPRX.
View Industry Companies

Industry Analysis


Industry Average

Valuation RPRX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.0x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact REPROS THERAPEUTICS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at